News Release

Health Catalyst Reports Second Quarter 2021 Results

News Release

Health Catalyst Reports Second Quarter 2021 Results

August 5, 2021 at 4:03 PM EDT

SALT LAKE CITY, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended June 30, 2021.

“In the second quarter of 2021, I am pleased to share that we achieved strong performance across our business, including exceeding the mid-point of our quarterly guidance for both revenue and Adjusted EBITDA. Our second quarter 2021 Adjusted EBITDA performance of $1.7 million represents the first time since the company’s incorporation that we have achieved positive quarterly Adjusted EBITDA,” said Dan Burton, CEO of Health Catalyst. “Additionally, we are excited to have closed our recent acquisition of Twistle on July 1, 2021. We anticipate Twistle will meaningfully bolster our Population Health analytics application suite, as healthcare organizations increasingly look for a comprehensive Population Health solution. This is particularly important as healthcare organizations begin to normalize operations outside of COVID-19, with many reprioritizing their transition to value-based care models and optimizing care delivery in virtual settings. We are thrilled to welcome our highly talented Twistle teammates to Health Catalyst, further enabling our mission to be the catalyst for massive, measurable, data-informed healthcare improvement.”

Financial Highlights for the Three Months Ended June 30, 2021

Key Financial Metrics

 Three Months Ended June 30, Year over Year
Change

 2021 2020 
               
             
 (in thousands, except percentages, unaudited)
GAAP Financial Data:            
Technology revenue$35,529   $25,487   39%
Professional services revenue$24,098   $17,772   36%
Total revenue$59,627   $43,259   38%
Loss from operations$(32,319)  $(15,640)  (107)%
Net loss$(35,834)  $(27,183)  (32)%
Other Non-GAAP Financial Data:(1)     
Adjusted Technology Gross Profit$24,256   $17,493   39%
Adjusted Technology Gross Margin68 % 69 %  
Adjusted Professional Services Gross Profit$8,174   $3,730   119%
Adjusted Professional Services Gross Margin34 % 21 %  
Total Adjusted Gross Profit$32,430   $21,223   53%
Total Adjusted Gross Margin54 % 49 %  
Adjusted EBITDA$1,661   $(4,188)  140%

_____________________
(1) These measures are not calculated in accordance with generally accepted accounting principles in the United States (GAAP). See the accompanying "Non-GAAP Financial Measures" section below for more information about these financial measures, including the limitations of such measures, and for a reconciliation of each measure to the most directly comparable measure calculated in accordance with GAAP.

Financial Outlook

Health Catalyst provides forward-looking guidance on total revenue, a GAAP measure, and Adjusted EBITDA, a non-GAAP measure.

For the third quarter of 2021, we expect:

  • Total revenue between $59.4 million and $62.4 million, and
  • Adjusted EBITDA between $(7.5) million and $(5.5) million

For the full year of 2021, we expect:

  • Total revenue between $236.7 million and $239.7 million, and
  • Adjusted EBITDA between $(12.5) million and $(10.5) million

We have not reconciled guidance for Adjusted EBITDA to net loss, the most directly comparable GAAP measure, and have not provided forward-looking guidance for net loss, because there are items that may impact net loss, including stock-based compensation, that are not within our control or cannot be reasonably predicted.

Quarterly Conference Call Details

The company will host a conference call to review the results today, Thursday, August 5, 2021, at 5:00 p.m. E.T. The conference call can be accessed by dialing 1-800-708-4539 for U.S. participants, or 1-847-619-6396 for international participants, and referencing participant code 50199342. A live audio webcast will be available online at https://ir.healthcatalyst.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Health Catalyst

Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations committed to being the catalyst for massive, measurable, data-informed healthcare improvement. Its customers leverage the cloud-based data platform—powered by data from more than 100 million patient records and encompassing trillions of facts—as well as its analytics software and professional services expertise to make data-informed decisions and realize measurable clinical, financial, and operational improvements. Health Catalyst envisions a future in which all healthcare decisions are data informed.

Available Information

Health Catalyst intends to use its Investor Relations website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding our future growth, the benefits of the Twistle acquisition, the impact of COVID-19 on our business and results of operations and our financial outlook for Q3 and fiscal year 2021. Forward-looking statements are subject to risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance.

Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market or industry conditions, regulatory environment and receptivity to our technology and services; (iii) results of litigation or a security incident; (iv) the loss of one or more key customers or partners; (v) the impact of COVID-19 on our business and results of operations; and (vi) changes to our abilities to recruit and retain qualified team members. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to the Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on or about February 25, 2021 and the Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2021 expected to be filed with the SEC on or about August 6, 2021. All information provided in this release and in the attachments is as of the date hereof, and we undertake no duty to update or revise this information unless required by law.

 
 
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data, unaudited)
 
 As of
June 30,
 As of
December 31,
 2021 2020
Assets       
Current assets:       
Cash and cash equivalents$205,095  $91,954 
Short-term investments57,661  178,917 
Accounts receivable, net46,971  48,296 
Prepaid expenses and other assets11,323  10,632 
Total current assets321,050  329,799 
Property and equipment, net20,198  12,863 
Intangible assets, net85,910  98,921 
Operating lease right-of-use assets23,450  24,729 
Goodwill107,822  107,822 
Other assets4,526  3,606 
Total assets$562,956  $577,740 
Liabilities and stockholders’ equity   
Current liabilities:   
Accounts payable$5,259  $5,332 
Accrued liabilities13,979  16,510 
Acquisition-related consideration payable  2,000 
Deferred revenue55,594  47,145 
Operating lease liabilities2,327  2,622 
Contingent consideration liabilities2,625  14,427 
Convertible senior notes, net174,811   
Total current liabilities254,595  88,036 
Convertible senior notes, net of current portion  168,994 
Deferred revenue, net of current portion894  1,878 
Operating lease liabilities, net of current portion22,504  23,669 
Contingent consideration liabilities, net of current portion6,827  16,837 
Other liabilities2,232  2,227 
Total liabilities287,052  301,641 
Commitments and contingencies       
Stockholders’ equity:       
Common stock, $0.001 par value; 45,611,225 and 43,376,848 shares issued and outstanding as     
of June 30, 2021 and December 31, 2020, respectively46  43 
Additional paid-in capital1,065,680  1,001,645 
Accumulated deficit(789,854) (725,650)
Accumulated other comprehensive income32  61 
Total stockholders' equity275,904  276,099 
Total liabilities and stockholders’ equity$562,956  $577,740 
        


Condensed Consolidated Statements of Operations
(in thousands, except per share data, unaudited)
    
 Three Months Ended
June 30,
 Six Months Ended
June 30,
 2021 2020 2021 2020
Revenue:       
Technology        $35,529   $25,487   $69,368   $50,186  
Professional services        24,098   17,772   46,105   38,189  
Total revenue        59,627   43,259   115,473   88,375  
Cost of revenue, excluding depreciation and amortization:       
Technology(1)        11,847   8,197   22,672   16,103  
Professional services(1)        18,206   14,932   34,719   31,094  
Total cost of revenue, excluding depreciation and amortization        30,053   23,129   57,391   47,197  
Operating expenses:       
Sales and marketing(1)        16,705   12,502   32,356   25,989  
Research and development(1)        14,524   12,061   28,869   25,149  
General and administrative(1)(2)(3)        22,525   8,113   37,540   17,814  
Depreciation and amortization        8,139   3,094   15,953   5,971  
Total operating expenses        61,893   35,770   114,718   74,923  
Loss from operations        (32,319) (15,640) (56,636) (33,745)
Loss on extinguishment of debt        —   (8,514) —   (8,514)
Interest and other expense, net        (3,707) (3,025) (7,659) (3,646)
Loss before income taxes        (36,026) (27,179) (64,295) (45,905)
Income tax (benefit) provision        (192)   (91) (1,232)
Net loss        $(35,834) $(27,183) $(64,204) $(44,673)
Net loss per share, basic and diluted        $(0.80) $(0.71) $(1.45) $(1.19)
Weighted-average shares outstanding used in calculating net loss
per share, basic and diluted        
44,886   38,131   44,381   37,620  
        
Adjusted net loss(4)        $(1) $(5,740) (2,754) (11,823)
Adjusted net loss per share, basic and diluted(4)        $—   $(0.15) $(0.06) $(0.31)

______________________
(1)   Includes stock-based compensation expense as follows:

    
 Three Months Ended
June 30,
 Six Months Ended
June 30,
 2021 2020 2021 2020
            
Stock-Based Compensation Expense:(in thousands) (in thousands)   
Cost of revenue, excluding depreciation and amortization:       
Technology$574  $203  $948  $379 
Professional services2,282  890  3,717  1,706 
Sales and marketing5,932  3,309  10,750  6,491 
Research and development2,676  2,080  4,933  3,962 
General and administrative6,263  2,564  10,889  5,249 
Total$17,727  $9,046  $31,237  $17,787 

(2)   Includes acquisition-related costs, net as follows:

 Three Months Ended
June 30,
 Six Months Ended
June 30,
 2021 2020 2021 2020
                
Acquisition-related costs, net:(in thousands) (in thousands)
General and administrative$8,114  $(813) $10,270  $(297)

(3)   Includes duplicate headquarters rent expense, as follows:

 Three Months Ended
June 30,
 Six Months Ended
June 30,
 2021 2020 2021 2020
Duplicate rent expense(in thousands) (in thousands)
General and administrative$  $125  $  $125 

(4)   Includes non-GAAP adjustments to net loss. Refer to the "Non-GAAP Financial Measures—Adjusted Net Loss Per Share" section below for further details.

 
Condensed Consolidated Statements of Cash Flows
(in thousands, unaudited)
 
 Six Months Ended
June 30,
Cash flows from operating activities2021 2020
Net loss$(64,204) $(44,673)
Adjustments to reconcile net loss to net cash used in operating activities:   
Depreciation and amortization15,953  5,971 
Loss on extinguishment of debt  8,514 
Amortization of debt discount and issuance costs5,817  2,540 
Non-cash operating lease expense1,926  1,569 
Investment discount and premium amortization569  267 
Provision for expected credit losses398  836 
Stock-based compensation expense31,237  17,787 
Deferred tax (benefit) provision4  (1,280)
Change in fair value of contingent consideration liabilities9,064  (1,568)
Settlement of acquisition-related contingent consideration(11,025)  
Other(25) 71 
Change in operating assets and liabilities:   
Accounts receivable, net927  (7,179)
Deferred costs  482 
Prepaid expenses and other assets(1,548) (2,493)
Accounts payable, accrued liabilities, and other liabilities(2,439) (1,056)
Deferred revenue7,465  4,475 
Operating lease liabilities(2,107) (1,783)
Net cash used in operating activities(7,988) (17,520)
    
Cash flows from investing activities   
Purchase of short-term investments(53,686) (163,346)
Proceeds from the sale and maturity of short-term investments174,293  124,150 
Acquisition of businesses, net of cash acquired  (15,249)
Purchase of property and equipment(8,138) (789)
Capitalization of internal use software(1,912) (278)
Purchase of intangible assets(770) (1,182)
Proceeds from sale of property and equipment12  10 
Net cash provided by (used in) investing activities109,799  (56,684)
    
Cash flows from financing activities   
Proceeds from convertible note securities, net of issuance costs  222,482 
Purchase of capped calls concurrent with issuance of convertible senior notes  (21,743)
Repayment of credit facilities  (57,043)
Proceeds from exercise of stock options14,076  15,010 
Proceeds from employee stock purchase plan2,619  2,408 
Payments of acquisition-related consideration(5,360) (748)
Net cash provided by financing activities11,335  160,366 
Effect of exchange rate on cash and cash equivalents(5) (9)
Net increase in cash and cash equivalents113,141  86,153 
Cash and cash equivalents at beginning of period91,954  18,032 
Cash and cash equivalents at end of period$205,095  $104,185 
        

Non-GAAP Financial Measures

To supplement our financial information presented in accordance with GAAP, we believe certain non-GAAP measures, including Adjusted Gross Profit, Adjusted Gross Margin, Adjusted EBITDA, Adjusted Net Loss, and Adjusted Net Loss per share, basic and diluted, are useful in evaluating our operating performance. For example, we exclude stock-based compensation expense because it is non-cash in nature and excluding this expense provides meaningful supplemental information regarding our operational performance and allows investors the ability to make more meaningful comparisons between our operating results and those of other companies. We use this non-GAAP financial information to evaluate our ongoing operations, as a component in determining employee bonus compensation, and for internal planning and forecasting purposes.

We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP measures differently or may use other measures to evaluate their performance. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.

Adjusted Gross Profit and Adjusted Gross Margin

Adjusted Gross Profit is a non-GAAP financial measure that we define as revenue less cost of revenue, excluding depreciation and amortization and excluding stock-based compensation. We define Adjusted Gross Margin as our Adjusted Gross Profit divided by our revenue. We believe Adjusted Gross Profit and Adjusted Gross Margin are useful to investors as they eliminate the impact of certain non-cash expenses and allow a direct comparison of these measures between periods without the impact of non-cash expenses and certain other non-recurring operating expenses. The following is a reconciliation of revenue, the most directly comparable GAAP financial measure, to Adjusted Gross Profit, for the three months ended June 30, 2021 and 2020:

 Three Months Ended June 30, 2021
 (in thousands, except percentages)
 Technology Professional Services Total
Revenue$35,529   $24,098   $59,627  
Cost of revenue, excluding depreciation and amortization(11,847)  (18,206)  (30,053) 
Gross profit, excluding depreciation and amortization23,682   5,892   29,574  
Add:     
Stock-based compensation574   2,282   2,856  
Adjusted Gross Profit$24,256   $8,174   $32,430  
Gross margin, excluding depreciation and amortization67 % 24 % 50 %
Adjusted Gross Margin68 % 34 % 54 %


 Three Months Ended June 30, 2020
 (in thousands, except percentages)
 Technology Professional Services Total
Revenue$25,487   $17,772   $43,259  
Cost of revenue, excluding depreciation and amortization(8,197)  (14,932)  (23,129) 
Gross profit, excluding depreciation and amortization17,290   2,840   20,130  
Add:     
Stock-based compensation203   890   1,093  
Adjusted Gross Profit$17,493   $3,730   $21,223  
Gross margin, excluding depreciation and amortization68 % 16 % 47 %
Adjusted Gross Margin69 % 21 % 49 %

Adjusted EBITDA

Adjusted EBITDA is a non-GAAP financial measure that we define as net loss adjusted for (i) interest and other expense, net, (ii) loss on debt extinguishment, (iii) income tax (benefit) provision, (iv) depreciation and amortization, (v) stock-based compensation, (vi) acquisition-related costs, net, including the change in fair value of contingent consideration liabilities, and (vii) duplicate headquarters expense. We view acquisition-related expenses when applicable, such as transaction costs and changes in the fair value of contingent consideration liabilities that are directly related to business combinations as costs that are unpredictable, dependent upon factors outside of our control, and are not necessarily reflective of operational performance during a period. We believe Adjusted EBITDA provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance. The following is a reconciliation of our net loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA, for the three months ended June 30, 2021 and 2020:

 Three Months Ended
June 30,
 2021 2020
        
        
 (in thousands)
Net loss$(35,834) $(27,183)
Add:       
Interest and other expense, net3,707  3,025 
Loss on extinguishment of debt  8,514 
Income tax (benefit) provision(192) 4 
Depreciation and amortization8,139  3,094 
Stock-based compensation17,727  9,046 
Acquisition-related costs, net(1)8,114  (813)
Duplicate headquarters rent expense(2)  125 
Adjusted EBITDA$1,661  $(4,188)

_____________________
(1) Acquisition-related costs, net includes legal, due diligence, accounting, and consulting fees incurred as part of business combinations, and changes in fair value of contingent consideration liabilities for potential earn-out payments. For additional details refer to Note 2 in our condensed consolidated financial statements.
(2)   Duplicate rent expense for our corporate headquarters relocation.

Adjusted Net Loss Per Share

Adjusted Net Loss is a non-GAAP financial measure that we define as net loss adjusted for (i) stock-based compensation, (ii) amortization of acquired intangibles, (iii) loss on extinguishment of debt, (iv) acquisition-related costs, net, including the change in fair value of contingent consideration liabilities, (v) non-cash interest expense related to our convertible senior notes, and (vi) duplicate headquarters rent expense. We believe Adjusted Net Loss provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance.

  Three Months Ended June 30, Six Months Ended June 30,
  2021 2020 2021 2020
Numerator: (in thousands, except share and per share amounts)
Net loss $(35,834) $(27,183) $(64,204) $(44,673)
Add:                
Stock-based compensation 17,727  9,046  31,237  17,787 
Amortization of acquired intangibles 7,045  2,360  14,126  4,510 
Loss on extinguishment of debt   8,514    8,514 
Acquisition-related costs, net 8,114  (813) 10,270  (297)
Non-cash interest expense related to convertible senior notes 2,947  2,211  5,817  2,211 
Duplicate headquarters rent expense   125    125 
Adjusted Net Loss $(1) $(5,740) $(2,754) $(11,823)
Denominator:                
Weighted-average number of shares used in calculating net loss, basic and diluted 44,886,489  38,130,932  44,381,196  37,619,965 
Adjusted Net Loss per share, basic and diluted $  $(0.15) $(0.06) $(0.31)
                 

Health Catalyst Investor Relations Contact:
Adam Brown
Senior Vice President, Investor Relations and FP&A
+1 (855)-309-6800
ir@healthcatalyst.com

Health Catalyst Media Contact:
Amanda Hundt
Vice President, Corporate Communications
amanda.hundt@healthcatalyst.com
+1 (575) 491-0974